Harrow (HROW) Q1 2026 earnings review
Heavy Investments and Pricing Pains Mask Underlying Volume Growth
Harrow's Q1 2026 results represent a stark Reversing trend in both revenue and profitability, though management insists the decline is a temporary transition phase. Total revenue fell 8% YoY to $44.2M, dragging Adjusted EBITDA down to $(12.7M). The weakness was driven by a brutal $8M gross-to-net adjustment on its star drug VEVYE, as well as a pre-telegraphed channel destocking that practically zeroed out IHEEZO revenue. Despite the ugly headline numbers, underlying volume metrics are Accelerating. VEVYE prescriptions grew sequentially, and the company completed a massive 100-rep sales force expansion. Management held firm on their $350M-$365M full-year revenue guidance, betting that the painful Q1 upfront costs will translate into massive second-half operating leverage.
🐂 Bull Case
The company hired over 100 new sales representatives in 45 days. With the commercial infrastructure now fully scaled, subsequent revenue growth in H2 should drop directly to the bottom line.
VEVYE surpassed XIIDRA in monthly total prescriptions, reaching 14% market share. NRx grew 25% sequentially despite the broader dry eye market contracting, proving the drug's strong clinical appeal.
🐻 Bear Case
The unexpected $8M buy-down cost for VEVYE erased almost 30% of the drug's potential Q1 revenue. If high-deductible seasons continue to crush net pricing, Q1 profitability will be a structural issue every year.
With only $44.2M booked in Q1, Harrow must average over $100M per quarter for the rest of the year to hit its $350M-$365M target. Execution risk is extremely high.
⚖️ Verdict: ⚪
Neutral. The volume indicators (prescriptions, new accounts) support management's bullish thesis, but the severe miss on VEVYE's net pricing and the steep Q1 cash burn demand a "show-me" approach for the Q2 recovery.
Key Themes
VEVYE's $8M Gross-to-Net Surprise
Management previously touted the profitability of its new commercial coverage, but data contradicts this narrative for Q1. The surge of high-deductible patients forced Harrow to absorb massive buy-down costs, resulting in an $8M gross-to-net reduction. This Reversing pricing dynamic pushed VEVYE's recognized revenue down to $20.9M (flat YoY) despite skyrocketing prescription volumes. While management claims the "business rules" are fixed, this exposes a severe vulnerability to seasonal insurance resets.
IHEEZO Channel Destocking
As telegraphed in the prior quarter, IHEEZO revenue suffered a Decelerating shock, dropping to just $1.85M (down from $5.2M in 25Q1 and over $20M in recent quarters). This was entirely driven by the planned absorption of Q4 channel inventory. While unit demand actually grew 18% YoY, the extreme volatility in GAAP revenue recognition highlights the difficult working capital dynamics in the buy-and-bill market.
ImprimisRx Compounding Contraction
The legacy compounding business is Decelerating rapidly. ImprimisRx net revenue fell 33% YoY to $13.5M (down from $20.1M). While management has previously discussed shifting patients to higher-margin branded drugs (Project Beagle/Eagle), this segment's steep decline removes a reliable cash cow that historically stabilized the company's financials.
Sales Force Expansion Completed in Record Time
Harrow completed a massive scale-up, hiring over 100 new commercial representatives in roughly 45 days. This strategic investment is aimed squarely at making VEVYE the #1 cyclosporine therapy. While it punished Q1 margins (driving SG&A to $43.2M), it establishes the foundation for Accelerating volume growth in H2 2026.
TRIESENCE Momentum Building
TRIESENCE continues its Accelerating trajectory, with unit demand more than doubling (+136% YoY). This marks the sixth consecutive quarter of growth. The addition of 195 new accounts (28% of total ordering accounts) proves that the push into the surgical inflammation market is gaining highly durable traction.
Defying Macro Headwinds in Dry Eye
Harrow's volume performance stands in stark contrast to the macro environment. During Q1, total prescriptions in the overall dry eye market declined by 14%, and the branded dry eye segment dropped by 18%. Despite this, VEVYE grew TRx by 11% sequentially, proving it is actively cannibalizing market share from incumbents rather than relying on category expansion.
IOPIDINE 1% Procedural Synergy
IOPIDINE 1% represents a new synergy for the in-office procedural portfolio. With a permanent J-Code effective July 1, 2026, and WAC pricing set at $148 per pouch, it transitions from a capitated cost center to an accretive buy-and-bill asset. It can now be co-promoted with IHEEZO to retina specialists, treating post-procedural intraocular pressure spikes.
Other KPIs
A Reversing trend from the positive $19.6M generated in 25Q1. The cash burn was driven by the severe net loss and working capital swings, combined with the heavy upfront costs of the sales force expansion. However, the company maintains a healthy $94.6M cash buffer to absorb this investment phase.
SG&A is Accelerating, up from $40.5M YoY, fueled almost entirely by the onboarding of the new 100-person commercial team. This represents 97% of total quarterly revenue, illustrating extreme negative operating leverage in Q1 that must be reversed by sales execution in upcoming quarters.
Decelerating from 68% in 25Q1. Management attributed this compression primarily to the lower net revenue recognized per unit of VEVYE (the $8M GTN hit) and lower utilization of the ImprimisRx compounding facility.
Guidance
Accelerating significantly from the $44.2M reported in Q1. The midpoint ($76M) implies a ~72% sequential jump, relying on normalized VEVYE pricing, the resumption of IHEEZO restocking, and early contributions from the newly deployed sales force.
Accelerating vs FY25. Maintained from prior guidance. To achieve the $357.5M midpoint, Harrow must generate $313.3M over the next three quarters (averaging ~$104M per quarter). This implies a massive back-half hockey stick ramp.
Accelerating. Reaffirmed from previous communications. Given the $(12.7M) hole dug in Q1, Harrow must generate over $100M in Adjusted EBITDA in the remaining nine months, demanding flawless execution on gross-to-net pricing and OpEx leverage.
Key Questions
Preventing Future Gross-to-Net Shocks
The $8M GTN hit on VEVYE was blamed on high-deductible plan resets. Since deductibles reset every January, what structural 'business rules' changes have been implemented to prevent a repeat of this severe margin crush in Q1 2027?
ImprimisRx Baseline
With ImprimisRx compounded revenue dropping roughly 31% YoY to $13.5M, what is the new expected baseline for this segment? Is this intentional cannibalization via Project Beagle, or are there underlying operational headwinds?
IHEEZO Channel Inventory
You noted Q1 GAAP revenue for IHEEZO was essentially zero due to Q4 inventory burn. Are inventory levels at distributors now fully normalized, and should we expect Q2 GAAP revenue to perfectly match Q2 retail demand?
Sales Force ROI Timing
With 100 new reps deployed by mid-quarter, at what point in H2 do you expect them to reach full productivity and break even on their direct OpEx load?